UnknownNot Applicable

Pulmonary Rehabilitation for Uncontrolled Asthma Associated With Elevated BMI

United Kingdom180 participantsStarted 2017-05-11

Plain-language summary

Aim to evaluate the impact of a pulmonary rehabilitation (rehab) programme tailored and delivered to overweight and obese patients with difficult asthma on: 1. Asthma related quality of life (primary outcome) and asthma control (secondary outcome) 2. Treatment burden and healthcare usage (secondary outcomes) 3. Physical activity level, exercise tolerance, lung function and inflammation (secondary outcome) 4. Anxiety and depression (secondary outcome)

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Adults aged 18-80 year (smokers, ex-smokers and non-smokers)
✓. Confirmed asthma as per Global Initiative for Asthma (GINA) guidelines 2015\[4\] with characteristic symptoms and at least one of the following:
✓. Difficult asthma defined as per Scottish Intercollegiate Guidelines Network(SIGN)/British Thoracic Society(BTS) guideline 2014 as persistent symptoms and/or frequent asthma attacks despite treatment at step 4 or step 5 with either:
✓. BMI≥25 kg/m2
✓. MRC dyspnoea scale ≥3/5

Exclusion criteria

✕. ICU admission +/- mechanical ventilation in the previous year for asthma exacerbation
✕. Respiratory tract infection requiring antibiotics or asthma exacerbation requiring corticosteroid boost in preceding 4 weeks
✕. Significant respiratory or other co-morbidity likely to influence the conduct of the study
✕. Pregnancy and breast feeding
✕. Severe and/or unstable cardiac disease
✕. Impaired mobility that impacts on ability to participate in physical training
✕. Recent (within the preceding 6 months) commencement of antifungal, biologic (omalizumab, lebrikizumab, mepolizumab) or Airsonett device; eligible if on treatment for \>6months or discontinued \>6 months ago.

What they're measuring

AQLQ- Asthma quality of life questionnaire

Timeframe: 8 weeks

Trial details

NCT IDNCT03630432

SponsorNHS Greater Glasgow and Clyde

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2019-05-10

Contact for this trial

Douglas C Cowan

01412115451 douglas.cowan@ggc.scot.nhs.uk

View on ClinicalTrials.gov More Asthma trials